BROUSSARD BRUCE D 4

What Happened

• Bruce D. Broussard, a director of Takeda Pharmaceutical Co. Ltd. (TAK), was granted awards on 2026-07-01 consisting of 3,800 restricted stock units (RSUs) and 1,319 Tax Obligation Awards. Both grant lines are reported at $0.00 per share (awards, not open‑market purchases or sales).

Key Details

• Transaction date: July 1, 2026; Form 4 filed July 6, 2026 (reporting date / accession 0001395064-26-000268).
• Award amounts and reported values: 3,800 RSUs @ $0.00 (grant); 1,319 Tax Obligation Award units @ $0.00 (derivative). Total reported acquisition value = $0.
• Shares owned after transaction: not specified in this filing.
• Footnotes: F1 — RSUs represent a contingent right to one Ordinary Share each; RSUs convert into the equivalent number of American Depositary Shares upon vesting. RSUs vest on June 1, 2029. F2 — Tax Obligation Awards are economic equivalents that, upon vest, will be converted to a cash payment primarily to cover tax withholding using the then‑current market price.
• Transaction code: A = Award/Grant; the derivative line reflects a tax‑related award (not an option exercise).
• Timeliness: filing date is July 6, 2026 (transaction dated July 1, 2026); check the official Form 4 for any timeliness flags.

Context

• These are compensation awards (grants), not open‑market purchases or sales; such awards are routine director compensation and do not by themselves indicate buying or selling sentiment. The RSUs vest at a future date (June 1, 2029); the Tax Obligation Award is designed to cover tax liabilities on vesting and will be settled in cash.